| Novak, Urban |
| Completed | 2 | 72 | Europe | Rituximab, Methotrexate, Procarbazine, Lenalidomide, Radiotherapy, Temozolomide | International Extranodal Lymphoma Study Group (IELSG) | Primary Central Nervous System Lymphoma | 12/24 | 12/24 | | |
| Active, not recruiting | 2 | 175 | Europe | Ibrutinib, Rituximab | International Extranodal Lymphoma Study Group (IELSG), Janssen-Cilag AG, F. Hoffmann La Roche Ltd, Janssen Pharmaceutica NV | Marginal Zone Lymphoma, Nodal Marginal Zone Lymphoma, Splenic Marginal Zone Lymphoma | 06/27 | 06/27 | | |
SAKK 38/19, NCT04604067: Assessing a ctDNA and PET-oriented Therapy in Patients With DLBCL A Multicenter, Open-label, Phase II Trial. |
|
|
| Active, not recruiting | 2 | 260 | Europe | Acalabrutinib | Swiss Group for Clinical Cancer Research | Diffuse Large B-cell Lymphoma | 10/25 | 12/30 | | |
| Not yet recruiting | 1/2 | 10 | Europe | Donor-derived ex-vivo expanded EBV Tscm CTL | University Hospital, Basel, Switzerland | EBV Lymphoma, Post-transplant Lymphoproliferative Disease (PTLD) | 12/25 | 12/25 | | |
IMCAR, NCT06333275: Restoration of Immunity to Vaccine Preventable Diseases After CART-T Cell Therapy |
|
|
| Recruiting | N/A | 80 | Europe | Vaccines against: Diphtheria, tetanus, pertussis, polio, haemophilus influenza type b, varicella and measles | Insel Gruppe AG, University Hospital Bern | Vaccine Immunity in CAR-T Cell Therapy Recipients | 12/25 | 12/26 | | |
LIMPID, NCT05803616: Liquid Biopsy to Enable Diagnostics and Monitoring for Immune-mediated Lymphoproliferative Disorders |
|
|
| Recruiting | N/A | 20 | Europe | Liquid biopsy | University Hospital, Geneva | Lymphoproliferative Disorders, Lymphoproliferative Disorder Following Transplantation | 12/23 | 12/25 | | |
| Recruiting | N/A | 200 | Europe | Influenza vaccine | Insel Gruppe AG, University Hospital Bern | Influenza Vaccine, Immunocompromised Patients | 01/25 | 01/25 | | |
SAKK 38/23, NCT06090162: LIBERTY: Liquid Biopsy to Diagnose and Monitor CNS Involvement in High-risk B Cell Non-Hodgkin Lymphoma |
|
|
| Recruiting | N/A | 64 | Europe | ctDNA detection | Swiss Group for Clinical Cancer Research | Non-hodgkin Lymphoma, B Cell | 12/26 | 12/26 | | |
| Holbro, Andreas |
| Completed | 2 | 2 | Europe | Eltrombopag (Revolade®), standard therapy (without eltrombopag): HD-DXM | University Children's Hospital Basel, Stiftung zur Förderung medizinischer und biologischer Forschung, Novartis Pharmaceuticals, University of Erlangen-Nürnberg, Department of Biology | Primary Immune Thrombocytopenia (ITP) | 04/24 | 04/24 | | |
| Not yet recruiting | 1/2 | 10 | Europe | Donor-derived ex-vivo expanded EBV Tscm CTL | University Hospital, Basel, Switzerland | EBV Lymphoma, Post-transplant Lymphoproliferative Disease (PTLD) | 12/25 | 12/25 | | |
